NCT04176718 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions

Multiple MyelomaRefractory Multiple MyelomaMultiple Myeloma in RelapseRelapse

Interventions

DRUG

Daratumumab

predetermined dose, intravenously, at predetermined times per cycle

DRUG

Carfilzomib

predetermined dose, intravenously, give 3 times per cycle

DRUG

Pomalidomide

predetermined dose, orally, daily per cycle

DRUG

Dexamethasone

predetermined dose, orally, given 8 times per cycle

Trial Locations (3)

RECRUITING

Massachusetts General Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

RECRUITING

Beth Israel Deaconess Medical Center, Boston